Sol-Gel Technologies Ltd. (SLGL) 10-Year Financial Performance & Capital Metrics

SLGL • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutSol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.Show more

Revenue $12M +642.5%
EBITDA -$12M +59.3%
Net Income -$11M +61.2%
EPS (Diluted) -0.38 +62.4%
Gross Margin 97.98% +106.9%
EBITDA Margin -102.11% +94.5%
Operating Margin -104.13% +94.5%
Net Margin -91.7% +94.8%
ROE -31.35% +53.5%
ROIC -41.47% +40.3%
Debt/Equity 0.05 +6.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 98 (top 2%)
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Negative free cash flow
✗Sales declining 12.8% over 5 years
✗Expensive at 66.0x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-12.81%

3Y-28.28%

TTM282.9%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM66.87%

EPS CAGR

10Y-

5Y-

3Y-

TTM70.22%

ROCE

10Y Avg-172.5%

5Y Avg-37.26%

3Y Avg-45.21%

Latest-33.69%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	174K	129K	22.9M	8.77M	31.27M	3.88M	1.55M	11.54M
Revenue Growth %	-	-	-	-0.26%	176.55%	-0.62%	2.57%	-0.88%	-0.6%	6.42%
Cost of Goods Sold+	300K	359K	300K	28.15M	40.58M	27.91M	20.38M	12.68M	342K	233K
COGS % of Revenue	-	-	1.72%	218.19%	1.77%	3.18%	0.65%	3.27%	0.22%	0.02%
Gross Profit+	-300K	-359K	-126K	-28.02M	-17.67M	-19.14M	10.89M	-8.8M	-21.99M	11.3M
Gross Margin %	-	-	-0.72%	-217.19%	-0.77%	-2.18%	0.35%	-2.27%	-14.15%	0.98%
Gross Profit Growth %	-	-0.2%	0.65%	-221.36%	0.37%	-0.08%	1.57%	-1.81%	-1.5%	1.51%
Operating Expenses+	9.65M	20.76M	31.81M	33.65M	48.85M	11.09M	7.93M	7.45M	7.32M	23.32M
OpEx % of Revenue	-	-	182.8%	260.85%	2.13%	1.26%	0.25%	1.92%	4.71%	2.02%
Selling, General & Admin	2.46M	3.73M	6M	5.5M	8.28M	11.09M	8.45M	7.45M	7.37M	5.75M
SG&A % of Revenue	-	-	34.49%	42.67%	0.36%	1.26%	0.27%	1.92%	4.74%	0.5%
Research & Development	7.18M	17.02M	25.8M	28.15M	40.58M	27.91M	20.38M	12.68M	23.54M	17.8M
R&D % of Revenue	-	-	148.3%	218.19%	1.77%	3.18%	0.65%	3.27%	15.15%	1.54%
Other Operating Expenses	0	0	0	0	0	-27.91M	-20.91M	-12.68M	-23.6M	-233K
Operating Income+	-9.65M	-20.76M	-31.63M	-33.52M	25.95M	-30.23M	2.96M	-16.24M	-29.3M	-12.01M
Operating Margin %	-	-	-181.8%	-259.85%	1.13%	-3.45%	0.09%	-4.18%	-18.86%	-1.04%
Operating Income Growth %	-1.01%	-1.15%	-0.52%	-0.06%	1.77%	-2.17%	1.1%	-6.48%	-0.8%	0.59%
EBITDA+	-9.35M	-20.4M	-31.33M	-32.76M	26.84M	-29.29M	3.84M	-15.68M	-28.96M	-11.78M
EBITDA Margin %	-	-	-180.07%	-253.95%	1.17%	-3.34%	0.12%	-4.04%	-18.64%	-1.02%
EBITDA Growth %	-1.04%	-1.18%	-0.54%	-0.05%	1.82%	-2.09%	1.13%	-5.08%	-0.85%	0.59%
D&A (Non-Cash Add-back)	300K	359K	300K	762K	887K	946K	880K	562K	342K	233K
EBIT	-9.65M	-20.76M	-31.63M	-33.52M	-25.95M	-30.23M	2.96M	-16.24M	-29.3M	-10.58M
Net Interest Income+	0	0	65K	1.32M	1.37M	943K	257K	1.32M	2.07M	1.43M
Interest Income	0	0	65K	1.32M	1.37M	943K	257K	1.32M	2.07M	1.43M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	-13K	-15K	65K	1.32M	1.37M	943K	257K	1.32M	2.07M	1.43M
Pretax Income+	-9.66M	-20.77M	-31.57M	-32.2M	-24.58M	-29.29M	3.22M	-14.92M	-27.24M	-10.58M
Pretax Margin %	-	-	-181.43%	-249.64%	-1.07%	-3.34%	0.1%	-3.84%	-17.53%	-0.92%
Income Tax+	13K	15K	-65K	0	33K	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-9.66M	-20.77M	-31.57M	-32.2M	-24.61M	-29.29M	3.22M	-14.92M	-27.24M	-10.58M
Net Margin %	-	-	-181.43%	-249.64%	-1.07%	-3.34%	0.1%	-3.84%	-17.53%	-0.92%
Net Income Growth %	-0.99%	-1.15%	-0.52%	-0.02%	0.24%	-0.19%	1.11%	-5.63%	-0.83%	0.61%
Net Income (Continuing)	-9.66M	-20.77M	-31.57M	-32.2M	-24.61M	-29.29M	3.22M	-14.92M	-27.24M	-10.58M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.82	-1.77	-1.76	-1.80	-1.26	-1.30	0.14	-0.65	-1.01	-0.38
EPS Growth %	0.55%	-1.16%	0.01%	-0.02%	0.3%	-0.03%	1.11%	-5.64%	-0.55%	0.62%
EPS (Basic)	-0.82	-1.77	-1.76	-1.80	-1.26	-1.30	1.40	-0.65	-1.01	-0.38
Diluted Shares Outstanding	11.74M	11.74M	17.99M	17.87M	19.53M	22.57M	23.57M	23.13M	27.09M	27.86M
Basic Shares Outstanding	11.74M	11.74M	17.99M	17.87M	19.53M	22.57M	23.06M	23.13M	27.09M	27.86M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.14M	8.3M	10.55M	65.97M	55.79M	53.4M	57.11M	43.05M	41.17M	31.3M
Cash & Short-Term Investments	5.89M	7M	9.02M	62.99M	50.38M	50.17M	43.24M	33.63M	38M	23.93M
Cash Only	5.89M	7M	5.02M	5.33M	9.41M	7.12M	20.09M	12.45M	7.51M	19.49M
Short-Term Investments	0	0	4M	57.66M	40.97M	43.05M	23.16M	21.18M	30.48M	4.44M
Accounts Receivable	0	0	0	0	4.12M	2.15M	13.06M	7.92M	377K	3.6M
Days Sales Outstanding	-	-	-	-	65.66	89.6	152.49	744.48	88.55	113.73
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	244K	472K	0	0	0	0	0	0	2.79M	3.77M
Total Non-Current Assets+	2.1M	2.69M	4.77M	3.71M	5.51M	5.76M	12.08M	3.57M	4.12M	4.55M
Property, Plant & Equipment	785K	798K	2.31M	2.6M	4.35M	3.71M	2.55M	1.54M	2.15M	1.63M
Fixed Asset Turnover	-	-	0.08x	0.05x	5.26x	2.36x	12.25x	2.53x	0.72x	7.09x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	92K	0	1.77M	0	472K	0	8.7M	1.29M	1.28M	2.31M
Other Non-Current Assets	1.23M	1.89M	680K	1.1M	684K	2.05M	830K	749K	681K	608K
Total Assets+	8.24M	10.98M	15.31M	69.68M	61.3M	59.16M	69.19M	46.63M	45.29M	35.85M
Asset Turnover	-	-	0.01x	0.00x	0.37x	0.15x	0.45x	0.08x	0.03x	0.32x
Asset Growth %	2.46%	0.33%	0.39%	3.55%	-0.12%	-0.03%	0.17%	-0.33%	-0.03%	-0.21%
Total Current Liabilities+	19.14M	41.63M	67.2M	4.89M	6.5M	5.96M	11.69M	3.33M	4.52M	5.29M
Accounts Payable	311K	667K	534K	2.92M	1.71M	1.2M	766K	251K	154K	1.26M
Days Payables Outstanding	378.38	678.15	649.7	37.92	15.38	15.73	13.72	7.22	164.36	1.98K
Short-Term Debt	17.34M	37.34M	65.34M	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	0	0	0	0	0
Current Ratio	0.32x	0.20x	0.16x	13.48x	8.58x	8.95x	4.88x	12.93x	9.10x	5.92x
Quick Ratio	0.32x	0.20x	0.16x	13.48x	8.58x	8.95x	4.88x	12.93x	9.10x	5.92x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	626K	694K	810K	878K	2.33M	2.35M	1.9M	1.09M	2.12M	1.71M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.37M	1.3M	810K	54K	1.21M	878K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	626K	694K	810K	878K	958K	1.05M	1.09M	1.03M	915K	833K
Total Liabilities	19.76M	42.32M	68.01M	5.77M	8.84M	8.31M	13.6M	4.42M	6.64M	7M
Total Debt+	17.34M	37.34M	65.34M	0	2.04M	1.97M	1.59M	772K	1.65M	1.31M
Net Debt	11.44M	30.34M	60.31M	-5.33M	-7.37M	-5.15M	-18.49M	-11.68M	-5.86M	-18.18M
Debt / Equity	-	-	-	-	0.04x	0.04x	0.03x	0.02x	0.04x	0.05x
Debt / EBITDA	-	-	-	-	0.08x	-	0.41x	-	-	-
Net Debt / EBITDA	-	-	-	-	-0.27x	-	-4.81x	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	-11.52M	-31.34M	-52.7M	63.91M	52.47M	50.85M	55.59M	42.21M	38.64M	28.85M
Equity Growth %	-2.86%	-1.72%	-0.68%	2.21%	-0.18%	-0.03%	0.09%	-0.24%	-0.08%	-0.25%
Book Value per Share	-0.98	-2.67	-2.93	3.58	2.69	2.25	2.36	1.83	1.43	1.04
Total Shareholders' Equity	-11.52M	-31.34M	-52.7M	63.91M	52.47M	50.85M	55.59M	42.21M	38.64M	28.85M
Common Stock	82K	82K	82K	520K	561K	635K	638K	638K	774K	774K
Retained Earnings	-42.92M	-63.69M	-95.26M	-127.46M	-152.07M	-181.36M	-178.14M	-193.06M	-220.3M	-230.88M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.15M	-1.51M	-1.98M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.04M	-18.5M	-24.09M	-23.47M	-22.5M	-25.24M	-7.69M	-9.48M	-17.73M	-13.89M
Operating CF Margin %	-	-	-138.44%	-181.91%	-0.98%	-2.88%	-0.25%	-2.44%	-11.41%	-1.2%
Operating CF Growth %	-0.67%	-1.3%	-0.3%	0.03%	0.04%	-0.12%	0.7%	-0.23%	-0.87%	0.22%
Net Income	-9.66M	-20.77M	-31.57M	-32.2M	-24.61M	-29.29M	3.22M	-14.92M	-27.24M	-10.58M
Depreciation & Amortization	300K	359K	471K	762K	887K	946K	880K	562K	342K	233K
Stock-Based Compensation	1.13M	952K	3.97M	4.65M	2.55M	1.22M	687K	1.53M	1.86M	786K
Deferred Taxes	0	0	0	29K	65K	138K	-96K	0	0	0
Other Non-Cash Items	448K	8K	6.18M	-5K	50K	104K	55K	-188K	-361K	74K
Working Capital Changes	-261K	957K	-3.15M	3.33M	-1.45M	1.64M	-12.44M	3.54M	7.67M	-4.4M
Change in Receivables	0	0	0	0	-4.12M	1.97M	-18.31M	12.55M	7.54M	-4.2M
Change in Inventory	0	0	0	0	1.69M	0	0	0	0	0
Change in Payables	449K	2.5M	-2.49M	3.03M	938K	-542K	5.62M	-8.3M	1.47M	780K
Cash from Investing+	-210K	-391K	-5.94M	-54.73M	16.02M	-2.69M	19.87M	1.7M	-9.74M	26.69M
Capital Expenditures	-291K	-385K	-1.93M	-1.05M	-597K	-449K	-143K	-171K	-134K	-2K
CapEx % of Revenue	-	-	11.06%	8.16%	0.03%	0.05%	0%	0.04%	0.09%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	89K	9K	-4.01M	8K	-10K	-21K	-5K	0	74K	6K
Cash from Financing+	13.57M	20M	28M	78.82M	10.61M	26.46M	837K	15K	21.81M	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	44K	0	151K	332K	0	268K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-8.34M	-18.88M	-26.01M	-24.52M	-23.1M	-25.69M	-7.83M	-9.65M	-17.86M	-13.89M
FCF Margin %	-	-	-149.51%	-190.07%	-1.01%	-2.93%	-0.25%	-2.49%	-11.5%	-1.2%
FCF Growth %	-0.63%	-1.27%	-0.38%	0.06%	0.06%	-0.11%	0.7%	-0.23%	-0.85%	0.22%
FCF per Share	-0.71	-1.61	-1.45	-1.37	-1.18	-1.14	-0.33	-0.42	-0.66	-0.50
FCF Conversion (FCF/Net Income)	0.83x	0.89x	0.76x	0.73x	0.91x	0.86x	-2.39x	0.64x	0.65x	1.31x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	7K	34K	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-574.54%	-42.29%	-56.7%	6.05%	-30.52%	-67.37%	-31.35%
Return on Invested Capital (ROIC)	-	-	-717.3%	-75.96%	37.54%	-49.95%	5.37%	-36.02%	-69.42%	-41.47%
Gross Margin	-	-	-72.41%	-21718.6%	-77.17%	-218.24%	34.83%	-226.6%	-1414.86%	97.98%
Net Margin	-	-	-18142.53%	-24963.57%	-107.44%	-333.94%	10.3%	-384.32%	-1752.77%	-91.7%
Debt / Equity	-	-	-	-	0.04x	0.04x	0.03x	0.02x	0.04x	0.05x
FCF Conversion	0.83x	0.89x	0.76x	0.73x	0.91x	0.86x	-2.39x	0.64x	0.65x	1.31x
Revenue Growth	-	-	-	-25.86%	17655.04%	-61.71%	256.54%	-87.58%	-59.98%	642.47%

Revenue by Segment

	2022	2023	2024
License	3.88M	1.55M	9.8M
License Growth	-	-59.98%	530.37%
Royalty	-	-	1.62M
Royalty Growth	-	-	-
Service, Other	-	-	126K
Service, Other Growth	-	-	-

Revenue by Geography

	2022	2023	2024
CHINA	-	-	4.87M
CHINA Growth	-	-	-
ISRAEL	-	-	3.81M
ISRAEL Growth	-	-	-
SWITZERLAND	-	-	1.48M
SWITZERLAND Growth	-	-	-
Segment Geographical Groups Of Countries Group Five	-	-	691K
Segment Geographical Groups Of Countries Group Five Growth	-	-	-
CANADA	-	-	681K
CANADA Growth	-	-	-

Frequently Asked Questions

Growth & Financials

Sol-Gel Technologies Ltd. (SLGL) reported $6.6M in revenue for fiscal year 2024.

Sol-Gel Technologies Ltd. (SLGL) grew revenue by 642.5% over the past year. This is strong growth.

Sol-Gel Technologies Ltd. (SLGL) reported a net loss of $14.9M for fiscal year 2024.

Dividend & Returns

Sol-Gel Technologies Ltd. (SLGL) has a return on equity (ROE) of -31.4%. Negative ROE indicates the company is unprofitable.

Sol-Gel Technologies Ltd. (SLGL) had negative free cash flow of $13.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Sol-Gel Technologies Ltd. (SLGL) 10-Year Financial Performance & Capital Metrics

SLGL • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $12M +642.5%
EBITDA -$12M +59.3%
Net Income -$11M +61.2%
EPS (Diluted) -0.38 +62.4%
Gross Margin 97.98% +106.9%
EBITDA Margin -102.11% +94.5%
Operating Margin -104.13% +94.5%
Net Margin -91.7% +94.8%
ROE -31.35% +53.5%
ROIC -41.47% +40.3%
Debt/Equity 0.05 +6.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 98 (top 2%)
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Negative free cash flow
✗Sales declining 12.8% over 5 years
✗Expensive at 66.0x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-12.81%

3Y-28.28%

TTM282.9%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM66.87%

EPS CAGR

10Y-

5Y-

3Y-

TTM70.22%

ROCE

10Y Avg-172.5%

5Y Avg-37.26%

3Y Avg-45.21%

Latest-33.69%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	174K	129K	22.9M	8.77M	31.27M	3.88M	1.55M	11.54M
Revenue Growth %	-	-	-	-0.26%	176.55%	-0.62%	2.57%	-0.88%	-0.6%	6.42%
Cost of Goods Sold+	300K	359K	300K	28.15M	40.58M	27.91M	20.38M	12.68M	342K	233K
COGS % of Revenue	-	-	1.72%	218.19%	1.77%	3.18%	0.65%	3.27%	0.22%	0.02%
Gross Profit+	-300K	-359K	-126K	-28.02M	-17.67M	-19.14M	10.89M	-8.8M	-21.99M	11.3M
Gross Margin %	-	-	-0.72%	-217.19%	-0.77%	-2.18%	0.35%	-2.27%	-14.15%	0.98%
Gross Profit Growth %	-	-0.2%	0.65%	-221.36%	0.37%	-0.08%	1.57%	-1.81%	-1.5%	1.51%
Operating Expenses+	9.65M	20.76M	31.81M	33.65M	48.85M	11.09M	7.93M	7.45M	7.32M	23.32M
OpEx % of Revenue	-	-	182.8%	260.85%	2.13%	1.26%	0.25%	1.92%	4.71%	2.02%
Selling, General & Admin	2.46M	3.73M	6M	5.5M	8.28M	11.09M	8.45M	7.45M	7.37M	5.75M
SG&A % of Revenue	-	-	34.49%	42.67%	0.36%	1.26%	0.27%	1.92%	4.74%	0.5%
Research & Development	7.18M	17.02M	25.8M	28.15M	40.58M	27.91M	20.38M	12.68M	23.54M	17.8M
R&D % of Revenue	-	-	148.3%	218.19%	1.77%	3.18%	0.65%	3.27%	15.15%	1.54%
Other Operating Expenses	0	0	0	0	0	-27.91M	-20.91M	-12.68M	-23.6M	-233K
Operating Income+	-9.65M	-20.76M	-31.63M	-33.52M	25.95M	-30.23M	2.96M	-16.24M	-29.3M	-12.01M
Operating Margin %	-	-	-181.8%	-259.85%	1.13%	-3.45%	0.09%	-4.18%	-18.86%	-1.04%
Operating Income Growth %	-1.01%	-1.15%	-0.52%	-0.06%	1.77%	-2.17%	1.1%	-6.48%	-0.8%	0.59%
EBITDA+	-9.35M	-20.4M	-31.33M	-32.76M	26.84M	-29.29M	3.84M	-15.68M	-28.96M	-11.78M
EBITDA Margin %	-	-	-180.07%	-253.95%	1.17%	-3.34%	0.12%	-4.04%	-18.64%	-1.02%
EBITDA Growth %	-1.04%	-1.18%	-0.54%	-0.05%	1.82%	-2.09%	1.13%	-5.08%	-0.85%	0.59%
D&A (Non-Cash Add-back)	300K	359K	300K	762K	887K	946K	880K	562K	342K	233K
EBIT	-9.65M	-20.76M	-31.63M	-33.52M	-25.95M	-30.23M	2.96M	-16.24M	-29.3M	-10.58M
Net Interest Income+	0	0	65K	1.32M	1.37M	943K	257K	1.32M	2.07M	1.43M
Interest Income	0	0	65K	1.32M	1.37M	943K	257K	1.32M	2.07M	1.43M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	-13K	-15K	65K	1.32M	1.37M	943K	257K	1.32M	2.07M	1.43M
Pretax Income+	-9.66M	-20.77M	-31.57M	-32.2M	-24.58M	-29.29M	3.22M	-14.92M	-27.24M	-10.58M
Pretax Margin %	-	-	-181.43%	-249.64%	-1.07%	-3.34%	0.1%	-3.84%	-17.53%	-0.92%
Income Tax+	13K	15K	-65K	0	33K	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-9.66M	-20.77M	-31.57M	-32.2M	-24.61M	-29.29M	3.22M	-14.92M	-27.24M	-10.58M
Net Margin %	-	-	-181.43%	-249.64%	-1.07%	-3.34%	0.1%	-3.84%	-17.53%	-0.92%
Net Income Growth %	-0.99%	-1.15%	-0.52%	-0.02%	0.24%	-0.19%	1.11%	-5.63%	-0.83%	0.61%
Net Income (Continuing)	-9.66M	-20.77M	-31.57M	-32.2M	-24.61M	-29.29M	3.22M	-14.92M	-27.24M	-10.58M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.82	-1.77	-1.76	-1.80	-1.26	-1.30	0.14	-0.65	-1.01	-0.38
EPS Growth %	0.55%	-1.16%	0.01%	-0.02%	0.3%	-0.03%	1.11%	-5.64%	-0.55%	0.62%
EPS (Basic)	-0.82	-1.77	-1.76	-1.80	-1.26	-1.30	1.40	-0.65	-1.01	-0.38
Diluted Shares Outstanding	11.74M	11.74M	17.99M	17.87M	19.53M	22.57M	23.57M	23.13M	27.09M	27.86M
Basic Shares Outstanding	11.74M	11.74M	17.99M	17.87M	19.53M	22.57M	23.06M	23.13M	27.09M	27.86M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.14M	8.3M	10.55M	65.97M	55.79M	53.4M	57.11M	43.05M	41.17M	31.3M
Cash & Short-Term Investments	5.89M	7M	9.02M	62.99M	50.38M	50.17M	43.24M	33.63M	38M	23.93M
Cash Only	5.89M	7M	5.02M	5.33M	9.41M	7.12M	20.09M	12.45M	7.51M	19.49M
Short-Term Investments	0	0	4M	57.66M	40.97M	43.05M	23.16M	21.18M	30.48M	4.44M
Accounts Receivable	0	0	0	0	4.12M	2.15M	13.06M	7.92M	377K	3.6M
Days Sales Outstanding	-	-	-	-	65.66	89.6	152.49	744.48	88.55	113.73
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	244K	472K	0	0	0	0	0	0	2.79M	3.77M
Total Non-Current Assets+	2.1M	2.69M	4.77M	3.71M	5.51M	5.76M	12.08M	3.57M	4.12M	4.55M
Property, Plant & Equipment	785K	798K	2.31M	2.6M	4.35M	3.71M	2.55M	1.54M	2.15M	1.63M
Fixed Asset Turnover	-	-	0.08x	0.05x	5.26x	2.36x	12.25x	2.53x	0.72x	7.09x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	92K	0	1.77M	0	472K	0	8.7M	1.29M	1.28M	2.31M
Other Non-Current Assets	1.23M	1.89M	680K	1.1M	684K	2.05M	830K	749K	681K	608K
Total Assets+	8.24M	10.98M	15.31M	69.68M	61.3M	59.16M	69.19M	46.63M	45.29M	35.85M
Asset Turnover	-	-	0.01x	0.00x	0.37x	0.15x	0.45x	0.08x	0.03x	0.32x
Asset Growth %	2.46%	0.33%	0.39%	3.55%	-0.12%	-0.03%	0.17%	-0.33%	-0.03%	-0.21%
Total Current Liabilities+	19.14M	41.63M	67.2M	4.89M	6.5M	5.96M	11.69M	3.33M	4.52M	5.29M
Accounts Payable	311K	667K	534K	2.92M	1.71M	1.2M	766K	251K	154K	1.26M
Days Payables Outstanding	378.38	678.15	649.7	37.92	15.38	15.73	13.72	7.22	164.36	1.98K
Short-Term Debt	17.34M	37.34M	65.34M	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	0	0	0	0	0
Current Ratio	0.32x	0.20x	0.16x	13.48x	8.58x	8.95x	4.88x	12.93x	9.10x	5.92x
Quick Ratio	0.32x	0.20x	0.16x	13.48x	8.58x	8.95x	4.88x	12.93x	9.10x	5.92x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	626K	694K	810K	878K	2.33M	2.35M	1.9M	1.09M	2.12M	1.71M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.37M	1.3M	810K	54K	1.21M	878K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	626K	694K	810K	878K	958K	1.05M	1.09M	1.03M	915K	833K
Total Liabilities	19.76M	42.32M	68.01M	5.77M	8.84M	8.31M	13.6M	4.42M	6.64M	7M
Total Debt+	17.34M	37.34M	65.34M	0	2.04M	1.97M	1.59M	772K	1.65M	1.31M
Net Debt	11.44M	30.34M	60.31M	-5.33M	-7.37M	-5.15M	-18.49M	-11.68M	-5.86M	-18.18M
Debt / Equity	-	-	-	-	0.04x	0.04x	0.03x	0.02x	0.04x	0.05x
Debt / EBITDA	-	-	-	-	0.08x	-	0.41x	-	-	-
Net Debt / EBITDA	-	-	-	-	-0.27x	-	-4.81x	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	-11.52M	-31.34M	-52.7M	63.91M	52.47M	50.85M	55.59M	42.21M	38.64M	28.85M
Equity Growth %	-2.86%	-1.72%	-0.68%	2.21%	-0.18%	-0.03%	0.09%	-0.24%	-0.08%	-0.25%
Book Value per Share	-0.98	-2.67	-2.93	3.58	2.69	2.25	2.36	1.83	1.43	1.04
Total Shareholders' Equity	-11.52M	-31.34M	-52.7M	63.91M	52.47M	50.85M	55.59M	42.21M	38.64M	28.85M
Common Stock	82K	82K	82K	520K	561K	635K	638K	638K	774K	774K
Retained Earnings	-42.92M	-63.69M	-95.26M	-127.46M	-152.07M	-181.36M	-178.14M	-193.06M	-220.3M	-230.88M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.15M	-1.51M	-1.98M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.04M	-18.5M	-24.09M	-23.47M	-22.5M	-25.24M	-7.69M	-9.48M	-17.73M	-13.89M
Operating CF Margin %	-	-	-138.44%	-181.91%	-0.98%	-2.88%	-0.25%	-2.44%	-11.41%	-1.2%
Operating CF Growth %	-0.67%	-1.3%	-0.3%	0.03%	0.04%	-0.12%	0.7%	-0.23%	-0.87%	0.22%
Net Income	-9.66M	-20.77M	-31.57M	-32.2M	-24.61M	-29.29M	3.22M	-14.92M	-27.24M	-10.58M
Depreciation & Amortization	300K	359K	471K	762K	887K	946K	880K	562K	342K	233K
Stock-Based Compensation	1.13M	952K	3.97M	4.65M	2.55M	1.22M	687K	1.53M	1.86M	786K
Deferred Taxes	0	0	0	29K	65K	138K	-96K	0	0	0
Other Non-Cash Items	448K	8K	6.18M	-5K	50K	104K	55K	-188K	-361K	74K
Working Capital Changes	-261K	957K	-3.15M	3.33M	-1.45M	1.64M	-12.44M	3.54M	7.67M	-4.4M
Change in Receivables	0	0	0	0	-4.12M	1.97M	-18.31M	12.55M	7.54M	-4.2M
Change in Inventory	0	0	0	0	1.69M	0	0	0	0	0
Change in Payables	449K	2.5M	-2.49M	3.03M	938K	-542K	5.62M	-8.3M	1.47M	780K
Cash from Investing+	-210K	-391K	-5.94M	-54.73M	16.02M	-2.69M	19.87M	1.7M	-9.74M	26.69M
Capital Expenditures	-291K	-385K	-1.93M	-1.05M	-597K	-449K	-143K	-171K	-134K	-2K
CapEx % of Revenue	-	-	11.06%	8.16%	0.03%	0.05%	0%	0.04%	0.09%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	89K	9K	-4.01M	8K	-10K	-21K	-5K	0	74K	6K
Cash from Financing+	13.57M	20M	28M	78.82M	10.61M	26.46M	837K	15K	21.81M	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	44K	0	151K	332K	0	268K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-8.34M	-18.88M	-26.01M	-24.52M	-23.1M	-25.69M	-7.83M	-9.65M	-17.86M	-13.89M
FCF Margin %	-	-	-149.51%	-190.07%	-1.01%	-2.93%	-0.25%	-2.49%	-11.5%	-1.2%
FCF Growth %	-0.63%	-1.27%	-0.38%	0.06%	0.06%	-0.11%	0.7%	-0.23%	-0.85%	0.22%
FCF per Share	-0.71	-1.61	-1.45	-1.37	-1.18	-1.14	-0.33	-0.42	-0.66	-0.50
FCF Conversion (FCF/Net Income)	0.83x	0.89x	0.76x	0.73x	0.91x	0.86x	-2.39x	0.64x	0.65x	1.31x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	7K	34K	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-574.54%	-42.29%	-56.7%	6.05%	-30.52%	-67.37%	-31.35%
Return on Invested Capital (ROIC)	-	-	-717.3%	-75.96%	37.54%	-49.95%	5.37%	-36.02%	-69.42%	-41.47%
Gross Margin	-	-	-72.41%	-21718.6%	-77.17%	-218.24%	34.83%	-226.6%	-1414.86%	97.98%
Net Margin	-	-	-18142.53%	-24963.57%	-107.44%	-333.94%	10.3%	-384.32%	-1752.77%	-91.7%
Debt / Equity	-	-	-	-	0.04x	0.04x	0.03x	0.02x	0.04x	0.05x
FCF Conversion	0.83x	0.89x	0.76x	0.73x	0.91x	0.86x	-2.39x	0.64x	0.65x	1.31x
Revenue Growth	-	-	-	-25.86%	17655.04%	-61.71%	256.54%	-87.58%	-59.98%	642.47%

Revenue by Segment

	2022	2023	2024
License	3.88M	1.55M	9.8M
License Growth	-	-59.98%	530.37%
Royalty	-	-	1.62M
Royalty Growth	-	-	-
Service, Other	-	-	126K
Service, Other Growth	-	-	-

Revenue by Geography

	2022	2023	2024
CHINA	-	-	4.87M
CHINA Growth	-	-	-
ISRAEL	-	-	3.81M
ISRAEL Growth	-	-	-
SWITZERLAND	-	-	1.48M
SWITZERLAND Growth	-	-	-
Segment Geographical Groups Of Countries Group Five	-	-	691K
Segment Geographical Groups Of Countries Group Five Growth	-	-	-
CANADA	-	-	681K
CANADA Growth	-	-	-

Frequently Asked Questions

Growth & Financials

Sol-Gel Technologies Ltd. (SLGL) reported $6.6M in revenue for fiscal year 2024.

Sol-Gel Technologies Ltd. (SLGL) grew revenue by 642.5% over the past year. This is strong growth.

Sol-Gel Technologies Ltd. (SLGL) reported a net loss of $14.9M for fiscal year 2024.

Dividend & Returns

Sol-Gel Technologies Ltd. (SLGL) has a return on equity (ROE) of -31.4%. Negative ROE indicates the company is unprofitable.

Sol-Gel Technologies Ltd. (SLGL) had negative free cash flow of $13.9M in fiscal year 2024, likely due to heavy capital investments.